Loading Page
Dr. Michael Sang Hughes, MD is a medical oncologist in White Plains, NY specializing in medical oncology, physician, oncology (cancer care) and hematology (blood disorders). He graduated from Harvard Medical School. Dr. Michael Sang Hughes, MD is affiliated with NewYork-Presbyterian, ColumbiaDoctors and ColumbiaDoctors at NewYork-Presbyterian The One.
Dr. Michael Sang Hughes, MD graduated from Harvard Medical School. He has a state license in New York.
Medical School: Harvard Medical School
Licensed In: New York
Dr. Michael Sang Hughes, MD appears to accept the following insurance providers: Healthspring (Cigna Medicare), VNSNY CHOICE, World Trade Center Health Plan, ElderServe, Emblem/Hip, Affinity Health Plan, Empire Blue Cross Blue Shield Healthplus, Emblem/GHI, Empire Blue Cross/Blue Shield, GHI PPO, Group Health Incorporated (GHI), CIGNA PPO, CIGNA POS, Blue Shield PPO, CIGNA HMO, Aetna Signature Administrators, CIGNA EPO, Blue Shield HMO, EmblemHealth, MVP Health Care, WellCare, Blue Shield EPO, Medicaid Managed Care, MultiPlan, HealthSpring, United Healthcare PPO, United Healthcare POS, United Healthcare HMO, Aetna, UnitedHealthcare, Aetna POS, Vytra, Affinity Health Plan, MagnaCare, United Healthcare, HIP EPO, Great-West Healthcare, Medicare, Medicaid, Cigna, Empire BlueCross BlueShield HMO, Oxford HMO, 1199SEIU, Fidelis Care, HIP PPO, HIP POS, Healthfirst, HIP HMO, Empire BlueCross BlueShield PPO, Aetna EPO, Empire BlueCross BlueShield, Aetna PPO, Aetna HMO, Medicare - Traditional Medicare, VNSNY CHOICE - Medicare Managed Care, World Trade Center Health Plan - World Trade Center Health Plan, Healthfirst - Child/Family Health Plus, Healthfirst - Leaf (Exchange), AETNA - Medicare Managed Care, VNSNY CHOICE - Special Needs, MVP Health Care - Essential Plan, AETNA - NY Signature, Empire Blue Cross - EPO, MVP Health Care - HMO, Amida Care, Healthfirst - Medicare Managed Care, AETNA - Student Health, Amida Care - Special Needs, VNSNY CHOICE - SelectHealth, MVP Health Care - Child/Family Health Plus and ElderServe - Special Needs.
According to our sources, Dr. Michael Sang Hughes, MD accepts the following insurance providers:
Dr. Michael Sang Hughes, MD does not have any reviews yet, be the first to leave a review of Dr. Michael Sang Hughes, MD here: Leave a Review
These charts describe general payments received by Dr. Michael Sang Hughes, MD. Doctors may receive payments for a number of reasons, including meal compensation, travel compensation, and consulting.
|
$275
SARCLISA $275 |
|
|
$100
LYNPARZA $100 |
| $275 | |
| $100 |
Dr. Michael Hughes is an attending physician and Assistant Professor practicing at Columbia University Irving Medical Center. He received his A.B. in Classics magna cum laude from Harvard College and his MD cum laude from Harvard Medical School. He completed his Internal Medicine residency at the Johns Hopkins Bayview Medical Center and Hematology/Oncology fellowship at the Columbia University Irving Medical Center. He is a member of the American College of Physicians, the American Medical Association, the American Society of Hematology, and the American Society of Clinical Oncology. Dr. Hughes' research has explored the interplay between cancer and the immune system. As an undergraduate medical student, he studied immune checkpoint inhibitor-induced gastroenterocolitis. As a Johns Hopkins Physician Scientist Training Pathway Scholar during residency, he investigated outcomes in patients with peripheral T-cell lymphomas after haploidentical blood and marrow transplantation. As an NIH T32-supported fellow, he worked in the Lentzsch Laboratory to develop novel anti-AL amyloidosis fibril therapies. For his contributions, Dr. Hughes was awarded the 2024 ASCO/Conquer Cancer Young Investigator Award and the 2025 Amyloidosis Foundation Research Grant. Dr. Hughes cares primarily for patients with plasma cell disorders, including multiple myeloma, amyloidosis, MGUS, POEMS syndrome, and Waldenstrom's macroglobulinemia. His current translational research interests focus on machine learning/deep learning-assisted outcome prediction in these diseases and the ongoing development of novel anti-AL amyloidosis fibril strategies.
